Autopsy report · NCT01706523
Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders
Cause of deathNo reason given
Life of this trial
- Registered 11 months after it had already started.
- Ran for about 1 year 8 months before it stopped.
- 165 participants planned (an estimate, not an actual count).
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Seaside Therapeutics, Inc.
- Sponsor type
- Industry
- Conditions
- Autism Spectrum Disorders
- Interventions
- STX209 (arbaclofen)
- Participants
- 165 (planned, not actual)
- Sites
- 25
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.